NCT03427125View on ClinicalTrials.gov

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

1,559

Participants

Timeline

Start Date

January 8, 2018

Primary Completion Date

November 15, 2019

Study Completion Date

February 27, 2020

Conditions
Hyperphosphatemia
Interventions
DRUG

Tenapanor

Active Drug

DRUG

Placebo

Inactive Drug

DRUG

Sevelamer Carbonate

Active control

Trial Locations (2)

10461

Site 529, The Bronx

27157

Wake Forest School of Medicine, Winston-Salem

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY